Journals Library

An error occurred retrieving publication content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

The systematic review and economic evaluation found that both adalimumab and infliximab are likely to be considered cost-effective (dominant relative to standard care) as induction therapy in the treatment of severe Crohn’s disease (CD), and adalimumab (but not infliximab) is cost-effective for moderate CD, according to limits generally accepted by the National Institute for Health and Clinical Excellence. Neither drug is likely to be cost-effective as longer term maintenance therapy for moderate or severe disease

{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

J Dretzke, R Edlin, J Round, M Connock, C Hulme, J Czeczot, A Fry-Smith, C McCabe & C Meads.

J Dretzke 1, R Edlin 2, J Round 2, M Connock 1, C Hulme 2, J Czeczot 1, A Fry-Smith 1, C McCabe 2, C Meads 3,*

1 Department of Public Health & Epidemiology, University of Birmingham, Birmingham, UK
2 Institute of Health Sciences, University of Leeds, Leeds, UK
3 Centre for Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK
* Corresponding author Email: dretzkej@adf.bham.ac.uk

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Crossmark status check

Report Content

The full text of this issue is available as a PDF document from the Toolkit section on this page.

The full text of this issue is available as a PDF document from the Toolkit section on this page.

If you would like to receive a notification when this project publishes in the NIHR Journals Library, please submit your email address below.

Responses to this report

No responses have been published.

 

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors.  Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

By submitting your response, you are stating that you agree to the terms & conditions

An error has occurred in processing the XML document